Sun Trumps Canadian Rival To Acquire InSite
This article was originally published in PharmAsia News
India’s Sun has snapped up the US ophthalmology firm InSite Vision as it sets its sights on a play in the US branded eye care space, edging out previous bidder and Canadian biotech QLT.
You may also be interested in...
The Australian firm also buys out Glioblast to add to its capabilities in brain cancer. Meanwhile, India’s Sun Pharmaceutical acquires Auven’s Ocular Technologies, and GlaxoSmithKline partners with Fimbrion in urinary tract infections and with Zai Lab in autoimmune disorders.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.